Upgrade to SI Premium - Free Trial

H.C. Wainwright Reiterates Buy Rating on Verrica Pharmaceuticals (VRCA)

June 23, 2026 6:53 AM
H.C. Wainwright analyst Raghuram Selvaraju reiterated a Buy rating and $12.00 price target on Verrica Pharmaceuticals (NASDAQ: VRCA).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments